A phase 3 trial found that vosoritide increased growth velocity in children with hypochondroplasia. The one-year result is strong, but adult height and long-term safety remain unknown.
60-Second Clinical Brief
Research · September 12, 2026A phase 3 trial found that vosoritide increased growth velocity in children with hypochondroplasia. The one-year result is strong, but adult height and long-term safety remain unknown.
A targeted peptide increased annualized growth velocity by 2.33 centimeters per year over placebo in children with hypochondroplasia. The phase 3 result is clear. What that extra growth means for adult height, mobility, daily function, and long-term safety is not.
That distinction matters because this is not a small exploratory study dressed up as a breakthrough. CANOPY HCH-3 was a randomized, placebo-controlled phase 3 trial, and it met its prespecified primary endpoint by a wide statistical margin. It is also a one-year study of 81 children, built around growth velocity rather than the outcomes families will live with years later.
The honest reading sits between celebration and dismissal. Vosoritide changed bone growth in a rare condition that has no targeted therapy described in the published trial. The study did not finish the story.
Researchers enrolled children aged 3 to under 18 with genetically confirmed hypochondroplasia. Forty-one received once-daily subcutaneous vosoritide and 40 received placebo for 52 weeks. Dosing followed weight bands. The primary endpoint was the change from baseline in annualized growth velocity at week 52.
Growth velocity improved by a least-squares mean of 1.95 cm per year in the vosoritide group. It fell by 0.39 cm per year in the placebo group. The adjusted difference between groups was 2.33 cm per year, with a 95% confidence interval from 1.85 to 2.82. The two-sided P value was below 0.0001.
This is a large, precise effect on the endpoint the trial was designed to test. It also extends the earlier phase 2 signal. In that open-label study, 24 treated children gained 1.81 cm per year in absolute annualized growth velocity compared with their own six-month observation period. The phase 3 trial adds the missing placebo control and a larger, multicenter population.
The numbers still need careful language. Annualized growth velocity describes the pace of linear growth during the study window. It is not a direct measurement of final adult height. A child can grow faster for a year without the full difference carrying through puberty. The abstract also does not show that faster growth improved pain, movement, independence, body proportions, spinal outcomes, or quality of life.
Hypochondroplasia is usually caused by activating variants in FGFR3, the gene that encodes fibroblast growth factor receptor 3. FGFR3 acts as a brake on endochondral bone growth, the process that lengthens many bones through cartilage at the growth plate. In hypochondroplasia, that braking signal is too active.
Vosoritide is an analogue of C-type natriuretic peptide, or CNP. It acts through a counter-signaling pathway that can reduce the downstream effect of overactive FGFR3 signaling. The aim is not to edit the genetic variant. It is to change the biochemical instructions reaching growth-plate cells while those growth plates remain active.
This is the same general rationale behind vosoritide use in achondroplasia, another FGFR3-related skeletal dysplasia. But the conditions are not interchangeable. They can differ in clinical severity, body proportions, complications, and natural growth patterns. Evidence from achondroplasia helps explain the mechanism and safety background. It cannot answer whether children with hypochondroplasia receive the same long-term benefits or face the same risks.
A 2026 meta-analysis of CNP analogues in achondroplasia included 11 studies with 542 children. Four randomized trials with 326 participants were pooled. The average improvement in annualized growth velocity was 1.36 cm per year versus placebo, and standing height improved by 1.24 cm. The analysis found no short-term effect on the upper-to-lower body segment ratio. Those data support the drug class, but CANOPY HCH-3 is the more relevant test for hypochondroplasia.
At least one adverse event occurred in 87.8% of children assigned to vosoritide and 72.5% assigned to placebo. The primary paper's abstract reports no grade 3 or higher adverse events, no adverse events that caused treatment discontinuation, and no deaths.
That is a reassuring one-year result. It does not make the treatment risk-free. Daily injections create their own burden, and common mild events can matter when therapy may continue for years. In the earlier phase 2 hypochondroplasia study, injection-site reactions occurred in 83.3% of treated children, although no participant stopped because of an adverse event.
A separate 2026 case series deserves context rather than alarm. Investigators reported slipped capital femoral epiphysis, a hip growth-plate disorder, in five participants receiving vosoritide in trials of other genetic forms of short stature. Cases occurred in children with ACAN-related short stature, a RASopathy, or Turner syndrome. None occurred among the 24 participants with hypochondroplasia in the basket trial described by that report.
That pattern does not prove vosoritide causes the complication, and it does not establish a signal in hypochondroplasia. It does show why safety findings cannot be transferred casually across different genetic growth disorders. Longer treatment also matters: all five reported cases appeared after more than 12 months, beyond the controlled period of CANOPY HCH-3.
A height endpoint is attractive because it is objective and can change within a year. Families, however, may care more about what a child can do, whether treatment affects orthopedic complications, and how the child feels about therapy. Those questions require different tools and longer follow-up.
A small qualitative study interviewed 14 children and 21 caregivers from 20 families after more than two years of vosoritide exposure in clinical trials. Twelve families had hypochondroplasia; the rest represented other genetic short-stature conditions. Participants often described easier reaching and greater independence. Every interviewed child reported a change in daily-activity impacts, while 74% of caregivers did.
Those reports are useful because they point toward outcomes worth measuring. They are not controlled efficacy data. The study was cross-sectional, included several diagnoses, relied on recall, and selected families who had remained in trials for more than two years. It cannot tell us how much improvement came from treatment, growth with age, adaptation, or expectation.
The next strong study should connect centimeters to function. That means prespecified measures of mobility and daily activity, orthopedic and neurologic complications, body proportionality, treatment burden, and child-reported quality of life. Final adult height will take years to observe. So will uncommon adverse effects.
CANOPY HCH-3 moves vosoritide for hypochondroplasia from a plausible mechanism and a promising single-arm result to phase 3 evidence that the drug increases growth velocity over placebo. That is a meaningful upgrade in certainty for one specific outcome.
It does not establish regulatory approval for hypochondroplasia, and the study should not be read as a dosing guide. Vosoritide was administered in a monitored clinical trial using a weight-band regimen. Treatment decisions for a child with a rare skeletal dysplasia belong with a specialist team that can confirm the diagnosis, explain realistic goals, monitor growth plates, and separate disease-related complications from treatment-emergent events.
The trial was funded by BioMarin Pharmaceutical, and several authors listed BioMarin affiliations. Sponsor involvement does not erase a randomized result, but it belongs in the interpretation. Independent replication and transparent longer-term follow-up would reduce uncertainty.
The headline number is 2.33 cm per year. The more important point is what the trial design lets us say: vosoritide produced a real increase in one-year linear growth compared with placebo in children with hypochondroplasia.
What we cannot say is just as important. We do not yet know the average effect on adult height, whether body proportions change, whether orthopedic complications improve or worsen, or how years of daily injections affect children and families. The absence of severe adverse events over 52 weeks is encouraging, but rare and delayed problems need larger and longer datasets.
For peptide medicine, this is a useful example of precision rather than hype. A defined molecular pathway, a genetically characterized condition, and a controlled trial produced a measurable clinical effect. The next task is to show whether that effect becomes a durable benefit that children can feel in daily life.
Dauber A, et al. "A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia." NEJM Evidence, 2026. https://pubmed.ncbi.nlm.nih.gov/42713641/
Dauber A, et al. "A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design." Therapeutic Advances in Endocrinology and Metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/42694461/
Dauber A, et al. "Vosoritide treatment for children with hypochondroplasia: a phase 2 trial." EClinicalMedicine, 2024. https://pubmed.ncbi.nlm.nih.gov/38813446/
Kanakatti Shankar R, et al. "Slipped Capital Femoral Epiphysis during Vosoritide Therapy for Short Stature: A Case Series." Hormone Research in Paediatrics, 2026. https://pubmed.ncbi.nlm.nih.gov/42678892/
Seaforth R, et al. "Perceived Impact of Vosoritide on Health-Related Quality of Life in Children with Selected Genetic Causes of Short Stature." Hormone Research in Paediatrics, 2026. https://pubmed.ncbi.nlm.nih.gov/42696489/
Kamrul-Hasan ABM, et al. "Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs." Journal of the Endocrine Society, 2026. https://pubmed.ncbi.nlm.nih.gov/42306228/
Evidence grade: B. One randomized, placebo-controlled phase 3 trial shows a large and precise improvement in the prespecified growth-velocity endpoint, supported by earlier phase 2 evidence. The grade is limited by the small cohort, one-year follow-up, use of a surrogate endpoint rather than adult height or function, sponsor involvement, and unanswered long-term safety questions.
Medical disclaimer: This article is for education only and is not medical advice. Vosoritide is a prescription medicine, and the phase 3 study discussed here investigated hypochondroplasia in a monitored research setting. Do not start, stop, or change treatment based on this article. Decisions about a child's diagnosis, eligibility, dosing, monitoring, and risks should be made with a pediatric endocrinology or skeletal-dysplasia specialist. Oria exists to make peptide research easier to understand, not to replace clinical care.
